



## BÖLÜM 24

### Safra Kesesi Kanserlerine Güncel Cerrahi Yaklaşım

Recep ÇAĞLAR<sup>1</sup>

#### Epidemiyoloji

Safra kesesi kanseri safra yolları kanserleri içerisinde en sık görülen, gastrointestinal sistem kanserleri içinde ise 5. sırada yer alan, nadir görülen, genellikle geç tanı konan ve kötü прогнозlu tümörlerdir (1). Safra kesesi kanseri, coğrafi dağılımı ve demografik özellikleri yönünden farklılık gösterir. Amerika Birleşik Devletleri (ABD), Singapur ve Nijerya'da insidansı düşük iken, İsrail, Şili, Polonya, Japonya'nın bazı bölgeleri, Hindistan'ın kuzeyi, Bolivya ve Meksika'da ise insidansı yüksektir. Amerikan yerlileri ve Alaskalılarda 6-10 kez daha sık görülmektedir. Beyaz ırkta siyahlarla göre daha siktir (2). Türkiye'de safra kesesi kanseri insidansı 1.7 / 100.000'dir ve ABD'ye oldukça benzerdir (3).

Safra kesesi kanseri görülme sıklığı ileri yaşlarda artma eğilimindedir ve yedinci dekatta pik yapar. Kadınlarda erkeklerden 2-6 kat daha sık görülür (4). Safra kesesi kanse-

rinden ilk kez 1777 yılında Viyana'da Maximilian Stoll bahsetmiştir (5).

#### Etiyopatogenez

Safra kesesi kanseri için kolelitiazis, porselen safra kesesi, safra kesesi polipleri, kronik salmonella enfeksiyonu, konjenital safra kistikleri ve anormal pankreatikobiliyer kanal bileşkesini içeren kronik inflamasyonla ilişkili çeşitli durumlar risk faktörleri olarak kabul edilir (6).

Kolelitiazis, safra kesesi kanserinde en önemli etiyolojik faktördür. Patogenezde muhtemelen mukozal irritasyonun kronik inflamasyona neden olduğu tahmin edilmektedir. Kolelitiaziste safra kesesi kanseri insidansı %0.3 ile %3 arasındadır (7, 8). Safra kesesi kanserli olguların %75-90'ında birlikte kolelitiazis olmasına rağmen, kolelitiazisli olguların yalnızca %1'inde kanser gelişme riski mevcuttur (9).

<sup>1</sup> Genel Cerrahi/ Gastroenterolojik Cerrahi Uzmanı, Mersin Şehir Eğitim Araştırma Hastanesi, rcaglarr@gmail.com

pik stentleme uygulamasıdır. Gastrik çıkış obstrüksiyonu, ileri evre safra kesesi kanserli hastaların %30 kadarında görülür ve palyatif gastrojejunostomiden fayda görebilir (43).

## Sağkalım

Rezeksiyon sonrası sağkalımı etkileyen en önemli prognostik faktörlerler; Orijinal lezyonun T evrelemesi, LN tutulumunun kapsamı, metastaz ve sarılıktır (52).

AJCC (Amerikan Cerrahlar Koleji Ulusal Kanser Veri Tabanından) elde edilen verilere göre, safra kesesi kanserli hastalarda 5 yıllık sağkalım oranları; Evre 0'da %80, Evre I'de %50, Evre II'de %28, Evre IIIA'da %8, Evre IIIB'de %7, Evre IVA'da %4 ve Evre IVB'de %2'dir (73).

## Kaynaklar

1. Kalita D, Pant L, Singh S, et al. Impact of routine histopathological examination of gall bladder specimens on early detection of malignancy - a study of 4,115 cholecystectomy specimens. *Asian Pac J Cancer Prev.* 2013;14(5):3315-3318.
2. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. *Int J Cancer.* 2006;118:1591-1602.
3. International Agency for Research on Cancer. "Global cancer statistics 2018-GLOBOCAN 2018." Graph production: IARC (<http://gco.iarc.fr/today>) World Health Organization. Lyon, France (2018).
4. Konstantinidis IT, Deshpande V, Genevay M, et al. Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience. *Arch Surg.* 2009;144:441-447; discussion 447.
5. Stoll, M. (1977). *Rationis medendi in nosocomio pratico Vindobonensi.* (p.254). Pars prima; Sumtibus August Bernardi, Wien.
6. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. *Clin Epidemiol.* 2014;6:99-109.
7. Singh V, Trikha B, Nain C, et al. Epidemiology of gallstone disease in Chandigarh: a community-based study. *J Gastroenterol Hepatol.* 2001;16:560-563.
8. Csendes A, Becerra M, Rojas J, et al. Number and size of stones in patients with asymptomatic and symptomatic gallstones and gallbladder carcinoma: a prospective study of 592 cases. *J Gastrointest Surg.* 2000;4:481-485.
9. Stephan AE, Berger DL. Carcinoma in the porcelain gallbladder: a relationship revisited. *Surgery.* 2001;129(6):699-703.
10. Berk RN, Armbuster TG, Saltzstein SL. Carcinoma in the porcelain gallbladder. *Radiology.* 1973;106:29-31.
11. Cunningham SC, Alexander HR. Porcelain gallbladder and cancer: ethnicity explains a discrepant literature? *Am J Med.* 2007;120:e17-8.
12. Koshiol J, Wozniak A, Cook P, et al. *Salmonella enterica* serovar Typhi and gallbladder cancer: a case-control study and meta-analysis. *Cancer Med.* 2016;5:3310-3235.
13. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. *Hepatology.* 2011;54:1842-1852.
14. Ahrendt, S.A, Pitt, H.A. (2001). Biliary tract. In: Townsend CM Jr, Editor in Chief. *Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice.* (Section X. Abdomen, 16th ed. pp. 1076-1111). Philadelphia. W.B. Saunders Company.
15. Meyers, W.C. Jones, R.S. (1990). Disorders of the biliary system: V. Neoplasms. In: Meyers WC, Jones RS, Editors. *Textbook of Liver and Biliary System.* (pp. 319-350). Philadelphia. J.B. Lippincott Company
16. Wolin KY, Carson K, Colditz GA. Obesity and cancer. *Oncologist.* 2010;15:556-565.
17. Lai HC, Chang SN, Lin CC, et al. Does diabetes mellitus with or without gallstones increase the risk of gallbladder cancer? Results from a population-based cohort study. *J Gastroenterol.* 2013;48:856-865.
18. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for gallbladder cancer across the world. *HPB (Oxford).* 2008;10:327-331.
19. Gallahan WC, Conway JD. Diagnosis and management of gallbladder polyps. *Gastroenterol Clin North Am.* 2010;39:359-367.
20. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. *Gut Liver.* 2012;6:172-187.
21. Kamisawa T, Kuruma S, Chiba K, et al. Biliary carcinogenesis in pancreaticobiliary maljunction. *J Gastroenterol.* 2017;52:158-163.
22. Dutta U, Nagi B, Garg PK, et al. Patients with gallstones develop gallbladder cancer at an earlier age. *Eur J Cancer Prev.* 2005;14:381-385.
23. Lee MH, Gao YT, Huang YH, et al. A Metallomic Approach to Assess Associations of Serum Metal Levels With Gallstones and Gallbladder Cancer. *Hepatology.* 2020;71(3):917-928.
24. Ikoma T, Tsuchiya Y, Asai T, et al. Ochratoxin A Contamination of Red Chili Peppers from Chile, Bolivia and Peru, Countries with a High Incidence of Gallbladder Cancer. *Asian Pac J Cancer Prev.* 2015;16:5987-5991.
25. Rustagi T, Dasanu CA. Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and updates. *J Gastrointest Cancer.* 2012;43(2):137-147.
26. Roa I, de Aretxabala X, Morgan R, et al. Clinicopathological features of gallbladder polyps and adenomas. *Rev Med Chil.* 2004;132:673-679.

27. Terzi C, Sökmen S, Seçkin S, et al. Polypoid lesions of the gallbladder: report of 100 cases with special reference to operative indications. *Surgery*. 2000;127:622-627.
28. Khoo JJ, Nurul AM. A clinicopathological study of nine cases of gallbladder carcinoma in 1122 cholecystectomies in Johor, Malaysia. *Malays J Pathol*. 2008;30(1):21-26.
29. Regimbeau JM, Fuks D, Bachellier P, et al. Prognostic value of jaundice in patients with gallbladder cancer by the AFC-GBC-2009 study group. *Eur J Surg Oncol*. 2011;37:505-512.
30. Pawlik TM, Gleisner AL, Vigano L, et al. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. *J Gastrointest Surg*. 2007;11:1478-1486.
31. Emmett CD, Barrett P, Gilliam AD, et al. Routine versus selective histological examination after cholecystectomy to exclude incidental gallbladder carcinoma. *Ann R Coll Surg Engl*. 2015;97(7):526-529.
32. Duffy A, Capanu M, Abou-Alfa GK, et al. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). *J Surg Oncol*. 2008;98:485-489.
33. Gençosmanoğlu R, Şad O, Kir G, et al. Safra kesesi kanseri: iki olgu. *PTT Hastanesi Tip Dergisi*. 2000;22(3):164-170.
34. Gulwani HV, Gupta S, Kaur S. Incidental detection of carcinoma gall bladder in laparoscopic cholecystectomy specimens: A thirteen year study of 23 cases and literature review. *Indian J Surg Oncol*. 2015;6(1):30-35.
35. Agarwal AK, Kalayaraslan R, Singh S, et al. All cholecystectomy specimens must be sent for histopathology to detect inapparent gallbladder cancer. *HPB (Oxford)*. 2012;14(4):269-273.
36. Kim HJ, Lee SK, Jang JW, et al. Diagnostic role of endoscopic ultrasonography-guided fine needle aspiration of gallbladder lesions. *Hepatogastroenterology*. 2012;59:1691-1695.
37. Kumaran V, Gulati S, Paul B, et al. The role of dual-phase helical CT in assessing resectability of carcinoma of the gallbladder. *Eur Radiol*. 2002;12:1993-1999.
38. Lin HT, Liu GJ, Wu D, et al. Metastasis of primary gallbladder carcinoma in lymph node and liver. *World J Gastroenterol*. 2005;11(5):748-751.
39. Krishnani N, Shukla S, Jain M, et al. Fine needle aspiration cytology in xanthogranulomatous cholecystitis, gallbladder adenocarcinoma and coexistent lesions. *Acta Cytol*. 2000;44:508-514.
40. Akosa AB, Barker F, Desa L, et al. Cytologic diagnosis in the management of gallbladder carcinoma. *Acta Cytol*. 1995;39:494-498.
41. Davidson JT, Jin LX, Krasnick B, et al. Staging laparoscopy among three subtypes of extra-hepatic biliary malignancy: a 15-year experience from 10 institutions. *J Surg Oncol*. 2019;119:288-294.
42. Leung U, Pandit-Taskar N, Corvera CU, et al. Impact of pre-operative positron emission tomography in gallbladder cancer. *HPB (Oxford)*. 2014;16:1023-1030.
43. Kaushik SP. Current perspectives in gallbladder carcinoma. *J Gastroenterol Hepatol*. 2001;16:848-854.
44. Agarwal AK, Kalayaraslan R, Javed A, et al. The role of staging laparoscopy in primary gall bladder cancer an analysis of 409 patients: a prospective study to evaluate the role of staging laparoscopy in the management of gallbladder cancer. *Ann Surg*. 2013;258:318-323.
45. Adam A. Biliary radiology. *Current opinion in Gastroenterology*. 1971;7(5):777-783.
46. Taniguchi H, Sakagami J, Suzuki N, et al. Adenocarcinoma of the gallbladder clinically mimicking squamous cell carcinoma. *Int J Clin Oncol*. 2009;14(2):167-170.
47. Kim MJ, Kim KW, Kim SY, et al. Unusual malignant tumors of the gallbladder. *AJR Am J Roentgenol*. 2006;187(2):473-480.
48. D'Hondt M, Lapointe R, Benamira Z, et al. Carcinoma of the gallbladder: patterns of presentation, prognostic factors and survival rate. An 11-year single centre experience. *Eur J Surg Oncol*. 2013;39(6):548-553.
49. Lai CH, Lau WY. Gallbladder cancer—a comprehensive review. *Surgeon*. 2008;6(2):101-110.
50. Wakai T, Shirai Y, Sakata J, et al. Mode of hepatic spread from gallbladder carcinoma: an immunohistochemical analysis of 42 hepatectomized specimens. *Am J Surg Pathol*. 2010;34(1):65-74.
51. Ito M, Mishima Y, Sato T. An anatomical study of the lymphatic drainage of the gallbladder. *Surg Radiol Anat*. 1991;13(2):89-104.
52. Jayaraman S, Jarnagin WR. Management of gallbladder cancer. *Gastroenterol Clin North Am*. 2010;39:331-342.
53. S, Hua J, Liang C, et al. Proposed modification of the 8th edition of the AJCC staging system for pancreatic ductal adenocarcinoma. *Ann Surg*. 2019;269(5):944-950.
54. Tsilimigras DI, Hyer JM, Paredes AZ, et al. The optimal number of lymph nodes to evaluate among patients undergoing surgery for gallbladder cancer: correlating the number of nodes removed with survival in 6531 patients. *J Surg Oncol*. 2019;119(8):1099-1107.
55. Zhu AX, Pawlik TM, Kooby DA, et al. (2017). Gallbladder. In: Amin MB (Ed). *AJCC Cancer Staging Manual* (8th ed). Chicago, IL: Springer.
56. Shih SP, Schulick RD, Cameron JL, et al. Gallbladder cancer: the role of laparoscopy and radical resection. *Ann Surg*. 2007;245:893-901.
57. Zhu AX, Hong TS, Hezel AR, et al. Current management of gallbladder carcinoma. *Oncologist*. 2010;15(2):168-181.
58. Pilgrim C, Usatoff V, Evans PM. A review of the surgical strategies for the management of gallbladder carcinoma based on T stage and growth type of the tumour. *Eur J Surg Oncol*. 2009;35(9):903-907.
59. Miller G, Jarnagin WR. Gallbladder carcinoma. *Eur J Surg Oncol*. 2008;34(3):306-312.
60. Yi X, Long X, Zai H, et al. Unsuspected gallbladder carcinoma discovered during or after cholecystectomy: focus on appropriate radical re-resection according to

- the T-stage. *Clin Transl Oncol.* 2013;15(18):652–658.
- 61. Niu GC, Shen CM, Cui W, et al. Surgical treatment of advanced gallbladder cancer. *Am J Clin Oncol.* 2015;38:5-10.
  - 62. Ito H, Ito K, D'Angelica M, et al. Accurate staging for gallbladder cancer: Implications for surgical therapy and pathological assessment. *Ann Surg.* 2011;254:320-325.
  - 63. Kelly KJ, Dukleska K, Kuk D, et al. Prognostic significance of the highest peripancreatic lymph node in biliary tract adenocarcinoma. *Ann Surg Oncol.* 2014;21:979-985.
  - 64. Fong Y, Jarnagin W, Blumgart LH. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. *Ann Surg.* 2000;232:557-569.
  - 65. Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. *J Gastrointest Surg.* 2007;11:671-681.
  - 66. Bouvy ND, Marquet RL, Jeekel H, et al. Impact of gas(-less) laparoscopy and laparotomy on peritoneal tumor growth and abdominal wall metastases. *Ann Surg.* 1996;224:694-700.
  - 67. Maker AV, Butte JM, Oxenberg J, et al. Is port site resection necessary in the surgical management of gallbladder cancer? *Ann Surg Oncol.* 2012;19:409-417.
  - 68. Jin K, Lan H, Zhu T, et al. Gallbladder carcinoma incidentally encountered during laparoscopic cholecystectomy: how to deal with it *Clin Transl Oncol.* 2011;13(1):25–33.
  - 69. Chaudhari VA, Ostwal V, Patkar S, et al. Outcome of neoadjuvant chemotherapy in “locally advanced/borderline resectable” gallbladder cancer: the need to define indications. *HPB (Oxford).* 2018;20:841-847.
  - 70. Wang SJ, Lemieux A, Kalpathy-Cramer J, et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. *J Clin Oncol.* 2011;29(35):4627-4632.
  - 71. Mattiucci GC, Autorino R, D'Agostino GR, et al. Chemoradiation and brachytherapy in extrahepatic bile duct carcinoma. *Crit Rev Oncol Hematol.* 2014;90(1):58-67.
  - 72. Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. *J Clin Oncol.* 2012;30(16):1934-1940.
  - 73. Edge, S.B., Byrd, D.R., Compton, C.C., et al. eds. (2010). AJCC Cancer Staging Manual (7<sup>th</sup> ed). New York: Springer.